Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis
Authors:
- 30 March 2021
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (14) , 2170-2179
Abstract
Objective: To determine the effect of long-term anti-CD20 B-cell-depleting treatment on regulatory T cell immune subsets that are subnormal in untreated MS patients. Methods: 30 clinically stable MS patients, before and over 38 months of ocrelizumab treatment, were compared to 13 healthy controls, 29 therapy-naïve MS, 9 interferon-β-treated MS, 3 rituximab-treated MS, and 3 rituximab-treated patients with other autoimmune inflammatory diseases. CD8, CD28, CD4, and FOXP3 expression in peripheral blood mononuclear cells was quantitated with flow cytometry. Results: CD8+ CD28− regulatory cells rose from one-third of healthy control levels before ocrelizumab treatment (2.68% vs 7.98%), normalized by 12 months (13.5%), and rose to 2.4-fold above healthy controls after 18 months of ocrelizumab therapy (19.0%). CD4+ FOXP3+ regulatory cells were lower in MS than in healthy controls (7.98%) and showed slight long-term decreases with ocrelizumab. CD8+ CD28− and CD4+ FOXP3+ regulatory T cell percentages in IFN-β-treated MS patients were between those of untreated MS and healthy controls. Interpretation: Long-term treatment with ocrelizumab markedly enriches CD8+ CD28− regulatory T cells and corrects the low levels seen in MS before treatment, while slightly decreasing CD4+ FOXP3+ regulatory T cells. Homeostatic enrichment of regulatory CD8 T cells provides a mechanism, in addition to B cell depletion, for the benefits of anti-CD20 treatment in MS.Keywords
Funding Information
- Genentech
This publication has 36 references indexed in Scilit:
- IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosisJournal of Neuroimmunology, 2011
- Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosisAnnals of Neurology, 2010
- Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid ArthritisThe Open Rheumatology Journal, 2008
- Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitisMultiple Sclerosis Journal, 2008
- Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLEClinical Immunology, 2007
- FOXP3: Of Mice and MenAnnual Review of Immunology, 2006
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Phenotypic and functional characteristics of activated CD8+ cells: A CD11b−CD28− subset mediates noncytolytic functional suppressionClinical Immunology and Immunopathology, 1991
- Analysis of T regulator cell surface markers and functional properties in multiple sclerosisJournal of Neuroimmunology, 1984
- Suppressor cell function in multiple sclerosis: Correlation with clinical disease activityAnnals of Neurology, 1979